Latest Breaking News On - Luminosity m14 239 trial - Page 1 : comparemela.com

Telisotuzumab vedotin produced meaningful response rates and other clinically relevant outcomes in patients with c-Met protein overexpressed, EGFR wild-type, advanced or metastatic nonsquamous non–small cell lung cancer.

United statesRoss camidgeRoopal thakkarUniversity of colorado cancer centerColorado cancer centerLung cancerTeliso vNon small cell lung cancerLuminosity m14 239 trial